We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ALPMY market cap is 17.28B. The company's latest EPS is JPY 54.5483 and P/E is 0.17.
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 1.31T | 1.31T | 1.26T | 1.33T | 1.52T |
| Operating Income | 267.07B | 250.2B | 138.36B | 147.51B | 143.15B |
| Net Income | 222.27B | 195.41B | 120.59B | 124.09B | 98.71B |
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.9T | 2.32T | 2.27T | 2.33T | 2.46T |
| Total Liabilities | 639.25B | 1.03T | 887.51B | 872.09B | 948.56B |
| Total Equity | 1.26T | 1.29T | 1.39T | 1.46T | 1.51T |
| Year End 31 March 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 258.63B | 222B | 306.84B | 257.44B | 327.77B |
| Investing | -41.76B | -389.79B | -81.9B | -62.41B | -84.5B |
| Financing | -233.68B | 181.05B | -229.48B | -216.3B | -195.62B |
| Market Cap | 17.28B |
| Price to Earnings Ratio | 0.17 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 1.81B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.12 (1.25%) |
| Company Name | Astellas Pharma Inc (PK) |
| Address |
2-5-1 nihonbashi-honcho chuo, tokyo 103-8411 |
| Website | https://www.astellas.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
